A new dose response application is making it possible for toxicologists to investigate how genes respond to particular chemical compounds at different doses, and to perform benchmark dose analyses at the gene and pathway levels. This is creating the opportunity to model the potential adverse effects of chemical compounds without the need for animal testing.
The increasing availability and lower cost of genomics and other omics data means that information generation is no longer an issue. The big bottleneck for computational toxicologists is the availability of tools that will allow them to find relevant data from within their own organisations and put private figures into a wider context using emerging public data sets. Driving this requirement is the increasing adoption of adverse outcome pathways (AOPs) for risk assessment (Figure 1).1 This is a conceptual framework that can be used to link in vitro assay results to whole animal effects in a pathway context.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.